Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab 3-hour intraperitoneal infusion with or without prednisolone premedication in malignant ascites
NL-OMON35315Phase 4Not yet recruiting
- Sponsor
- Fresenius
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of catumaxomab and prednisolone in malignant ascites (2 arms), sponsored by Fresenius. Primary endpoints: Composite safety score and Puncture-free survival. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
catumaxomabprednisolone
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NL-OMON35315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35315.